Market Access has moved from a supporting consideration to a major influence on Commercial Performance in Pharma. In this episode, Abhay Jajoo, Rickey Mehta, and Geoff Woodall trace that evolution—from a 1990s model dominated by Salesforce activity, to the rise of Marketing Mix and Digital Engagement, and ultimately to an environment where Payer Control, Formulary Restrictions, Pricing, Reimbursement, and Access Strategy can materially shape Brand Performance.
Episode Highlights
- 06:25 The evolution of Pharma Commercial Influence from Salesforce-led promotion to a model where Market Access plays a much larger role.
- 09:00 Why Incremental Sales have become smaller over time as portfolios have shifted toward Chronic Products with higher carryover.
- 12:25 A real-world brand example showing how carryover, promotion, and Market Access contribute differently to Sales.
- 28:38 How payer dynamics can overturn Conventional targeting assumptions, including an example where 52% of the opportunity sat with non-called-on Physicians.
- 36:34 Why Pricing and Discounting can represent a major Commercial Investment—and why Public Policy adds another layer of complexity.
- 47:16 The Analytics journey from Data Enablement and Hygiene to BI, Advanced Analytics, and Data Science.
- 57:54 Why Flexibility, Agility, and an Outcome-first approach are essential for modern Market Access Analytics.
Key Takeaways
- Market Access should be evaluated alongside Sales and Marketing—not treated as a separate or downstream consideration.
- The relative impact of Market Access and promotion can vary significantly by product and segment, making segment-level analysis critical.
- Conventional targeting can miss important opportunities when payer coverage and formulary dynamics are not incorporated into the segmentation framework.